Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on October 7, 2004

Stroke. 2004
Published online before print October 7, 2004, doi: 10.1161/01.STR.0000143734.59507.88
A more recent version of this article appeared on November 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/11_suppl_1/2648    most recent
01.STR.0000143734.59507.88v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simpkins, J. W.
Right arrow Articles by Green, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simpkins, J. W.
Right arrow Articles by Green, P. S.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Acute coronary syndromes

Submitted on June 2, 2004
Accepted on June 2, 2004

Estrogen-Like Compounds for Ischemic Neuroprotection

James W. Simpkins PhD*; Shao-Hua Yang MD, PhD; Ran Liu MD; Evelyn Perez PhD; Zu Yun Cai PhD; Douglas F. Covey PhD; and Pattie S. Green PhD

From the Department of Pharmacology & Neuroscience (J.W.S., S.-H.Y., R.L., E.P.), University of North Texas Health Science Center, Fort Worth, Texas; the Department of Molecular Biology and Pharmacology (Z.Y.C., D.F.C.), Washington University School of Medicine, St. Louis, Mo; and the Department of Gerontology and Geriatric Medicine (P.S.G.), School of Medicine, University of Washington, Seattle, Wash.

* To whom correspondence should be addressed. E-mail: jsimpkin{at}hsc.unt.edu.

Abstract--We have synthesized a library of estrogen analogues, including enantiomers of estradiol and A-ring substituted estrogens. These compounds have reduced or no binding to either estrogen receptor-{alpha} or estrogen receptor-{beta}, exhibit enhanced neuroprotective activity in in vitro models, and are potent in protecting brain tissue from cerebral ischemia/reperfusion injury. These potent, nonfeminizing estrogen analogues are prime candidates for use in stroke neuroprotection.


Key words: estrogens • estrogen receptors • neuroprotection • stroke